Skip to main navigation

Top Bar Nav

Contact Us

Social Icons

linkedin twitter

About Nav

About

Pioneering Pathways

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories

Our Stories

News Nav

News

IR Nav

Investors

Careers Nav

Careers

Home News Press Release Archive

Press Release Archive

News Nav

News
Press Release Archive
Events Archive
Our Stories

Media Contact

Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc

Send Email
Ireland: +353 1 637 2141
US: 215-867-4948

Press Release Archive

Year

Jazz Pharmaceuticals Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

November 20, 2024

Jazz Pharmaceuticals to Participate in Citi's 2024 Global Healthcare Conference

November 19, 2024

Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results

November 6, 2024

Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia

October 31, 2024

Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024

October 23, 2024

Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

October 15, 2024

Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024

September 16, 2024

Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024

September 9, 2024

Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024

September 5, 2024

Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases

September 4, 2024

Pagination

First page
Previous page
…
Page 2
Page 3
Page 4
Page 5
Current page 6
Page 7
Page 8
Page 9
Page 10
…
Next page
Last page

Displaying 51 - 60 of 600

About Nav

About

Pioneering Pathways Nav

Pioneering Pathways

Medicines Nav

Medicines

Science Nav

Science

Our Purpose Nav

Our Purpose

Our Stories Nav

Our Stories

News Nav

News

Careers Nav

Careers

IR Nav

Investors

© 2026 Jazz Pharmaceuticals plc All Rights Reserved.

Legal Nav

Privacy Statement
U.S. Consumer Health Data Privacy Policy
Terms of Use
Social Media Global Guidelines
Your Privacy Choices
Sitemap